Axsome Therapeutics, Inc. (AXSM) — Financial statements
Income statement, balance sheet, and cash flow for Axsome Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 638↑65.5% | 386↑42.5% | 271↑440.8% | 50 | 0.00 | |
| Cost of Revenue | 47↑42.6% | 33↑27.8% | 26↑401.4% | 5 | 0.00 | |
| Gross Profit | 591↑67.7% | 352↑44.1% | 245↑445.4% | 45 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 183↓2.0% | 187↑91.0% | 98↑69.0% | 58↓0.2% | 58 | |
| General & Administrative Expenses | 0.00↓100.0% | 310↑39.2% | 223 | 0.00↓100.0% | 67 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 101↑0.9% | 100 | 0.00↑100.0% | -0.00 | |
| SG&A Expenses | 571↑38.7% | 411↑27.3% | 323↑102.9% | 159↑139.0% | 67 | |
| Other Expenses | 6↓81.5% | 35↓37.6% | 55↑643.5% | 7 | 0.00 | |
| Operating Expenses | 760↑20.1% | 633↑32.9% | 476↑112.1% | 225↑80.1% | 125 | |
| Total Costs & Expenses | 808↑21.2% | 666↑32.6% | 502↑118.6% | 230↑84.3% | 125 | |
| Operating Results | ||||||
| Operating Income | -169↑39.7% | -281↓21.0% | -232↓28.9% | -180↓44.2% | -125 | |
| Depreciation & Amortization | 9↑13.9% | 8↑16.4% | 7↑55.2% | 4↑5692.1% | 0.08 | |
| EBITDA | -168↑38.3% | -273↓21.2% | -225↓28.3% | -175↓40.7% | -125 | |
| EBIT | -177↑36.9% | -281↓21.0% | -232↓28.9% | -180↓44.2% | -125 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↑142.8% | -7↓1.8% | -6↑12.0% | -7↓28.8% | -6 | |
| Interest Income | 9 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 7↓0.2% | 7↑1.8% | 6↓12.0% | 7↑28.8% | 6 | |
| Non-Operating Income | 8 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -14↓120.3% | -7↓1.8% | -6↑12.0% | -7↓28.8% | -6 | |
| Income Before Tax | -184↑36.0% | -287↓20.5% | -238↓27.3% | -187↓43.5% | -130 | |
| Income Tax Expense | -0.53↓723.5% | 0.09↓91.1% | 0.96 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -183↑36.2% | -287↓20.1% | -239↓27.8% | -187↓43.5% | -130 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -183↑36.2% | -287↓20.1% | -239↓27.8% | -187↓43.5% | -130 | |
| Bottom-Line Net Income | -183↑36.2% | -287↓20.1% | -239↓27.8% | -187↓43.5% | -130 | |
| EPS (Basic) | -3.68↑38.6% | -5.99↓13.7% | -5.27↓14.6% | -4.60↓32.6% | -3.47 | |
| EPS (Diluted) | -3.68↑38.6% | -5.99↓13.7% | -5.27↓14.6% | -4.60↓32.6% | -3.47 | |
| Weighted Average Shares | 50↑3.8% | 48↑5.5% | 45↑11.7% | 41↑8.1% | 38 | |
| Weighted Average Diluted Shares | 50↑3.8% | 48↑5.5% | 45↑11.7% | 41↑8.1% | 38 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.